Please login to the form below
Calquence
This page shows the latest Calquence news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn
Following AZ’s success with Calquence (acalabrutinib) – a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor – TNB-486 will further diversify the company’s haematology pipeline that have the potential
Latest news
-
AZ’s BTK inhibitor Calquence fails in COVID-19 study
AstraZenea’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence has failed to improve survival and prevent respiratory failure in hospitalised COVID-19 patients. ... In a statement, AZ said that the results from the CALAVI trial do not impact the
-
AZ strengthens Daiichi Sankyo partnership with new ADC deal
Both cancer types are of particular interest for AZ as it plans to extend its oncology franchise beyond its approved therapies, which include PD-1 inhibitor Imfinzi (durvalumab), lymphoma treatment
-
GSK’s anti-BCMA drug leads crowded CHMP recommendations
AstraZeneca also received two positive opinions following the meeting, with a recommendation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia and a label extension of its PD-1 inhibitor Imfinzi (durvalumab)
-
AZ revenues rise, but it says coronavirus could hit 2020
Recently-approved for a new chronic lymphocytic leukaemia (CLL) indication, AZ’s rival to Johnson &Johnson’s blockbuster BTK inhibitor Imbruvica (ibrutinib) – Calquence (acalabrutinib) – also gathered momentum and contributed $56m in
-
EMA begins review of Kite’s CAR-T for mantle cell lymphoma
Current treatment options for MCL include AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) and Johnson &Johnson/AbbVie’s BTK inhibitor Imbruvica (ibrutinib).
More from news
Approximately 6 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
AstraZeneca: building a new ‘open innovation’ pharma company
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Springer Nature
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
